Astellas lays out new mid-term strategic plan it sees as overcoming looming major expiries while positioning the firm for growth in new areas and a more than doubling in market cap.

Plus deals involving AbbVie/Mitokinin, Roivant/Silicon Therapeutics, CASI/Cleave Therapeutics, Tallac/ALX Oncology, AgeX/LyGenesis, Chinook/Evotec and more.

Astellas Pharma US accounts for roughly one-third of the parent company’s annual revenues with a growing focus on immuno-oncology. The unit’s president discusses lessons from the pandemic, racial disparities in health care and business development.

Japanese major builds presence in novel device technology beyond its conventional therapeutics as looks towards a more holistic future of care.